Zymeworks Advances Solid Tumor Strategy with Five IND Applications Nomination and Expansion into Autoimmune Diseases
Zymeworks advances solid tumor and autoimmune disease therapies, including five IND applications ahead of schedule and innovative drug candidates.Quiver AI SummaryZymeworks Inc. has made significant progress...
Zymeworks Inc. Management to Participate in Multiple Upcoming Investor Conferences and R&D Day
Zymeworks Inc. announces management participation in several upcoming investor conferences and a Research & Development Day.Quiver AI SummaryZymeworks Inc., a clinical-stage biotechnology company focused...
Zymeworks Inc. Announces FDA Accelerated Approval of Ziihera® for HER2-Positive Biliary Tract Cancer, the First Dual HER2-Targeted Bispecific Antibody Approved in the U.S.
Ziihera is the first FDA-approved bispecific antibody for HER2-positive biliary tract cancer, achieving a 52% response rate.Quiver AI SummaryZymeworks Inc. announced that the U.S. FDA has granted accelerated...